Ghrelin deficiency in patients with type 2 diabetes: the relationships with obesity, adipose tissue dysfunction and glucose variability


Cite item

Full Text

Abstract

Aim. Ghrelin, a peptide hormone mostly produced by stomach, plays an important role in regulation of feeding behavior, energy balance and glucose homeostasis. The aim: to determine the relationships between fasting serum levels of ghrelin, body composition, adipose tissue endocrine function and glucose variability (GV) in type 2 diabetic subjects with and without obesity. Materials and methods. We observed 124 individuals with type 2 diabetes, including 42 non - obese subjects and 82 patients with obesity. Thirty non - obese healthy subjects were acted as control. The concentrations of ghrelin, leptin, resistin, and visfatin in the fasting serum were determined by Multiplex analysis. Body composition was assessed with DEXA. The 24-hour and nocturnal GV parameters were derived from continuous glucose monitoring. Results and discussion. Ghrelin levels in patients with diabetes were decreased significantly as compared to control (p<0.00001). Subjects with obesity demonstrated lower ghrelin concentrations then non - obese patients (p=0.002). The levels of ghrelin correlated negatively with body mass index, total and gynoid fat mass. Total fat mass was most reliable predictor of ghrelin concentration in multiple regression analysis (R2=0.18). In patients with diabetes significant increase in the levels of leptin, resistin and visfatin was revealed (all p<0.001). Ghrelin correlated negatively with resistin and visfatin levels. Positive correlations were found between ghrelin and nocturnal GV parameters: SD, Mean Amplitude of Glucose Excursions, and High Blood Glucose Index. Conclusion. The reduced fasting serum level of ghrelin is associated with obesity, adipose tissue dysfunction and nocturnal GV in subjects with type 2 diabetes.

About the authors

V V Klimontov

Research Institute of Clinical and Experimental Lymphology - Branch of the Institute of Cytology and Genetics

Email: klimontov@mail.ru
д.м.н., зам. руководителя филиала по научной работе, зав. лабораторией эндокринологии Novosibirsk, Russia

D M Bulumbaeva

Research Institute of Clinical and Experimental Lymphology - Branch of the Institute of Cytology and Genetics

м.н.с. лаб. эндокринологии Novosibirsk, Russia

O N Fazullina

Research Institute of Clinical and Experimental Lymphology - Branch of the Institute of Cytology and Genetics

м.н.с. лаб. эндокринологии Novosibirsk, Russia

N B Orlov

Research Institute of Clinical and Experimental Lymphology - Branch of the Institute of Cytology and Genetics

к.м.н., с.н.с. лаб. клинической иммуногенетики Novosibirsk, Russia

V I Konenkov

Research Institute of Clinical and Experimental Lymphology - Branch of the Institute of Cytology and Genetics

д.м.н., проф., академик РАН, научный руководитель филиала, зав. лаб. клинической иммуногенетики Novosibirsk, Russia

References

  1. Global report on diabetes. World Health Organization, 2016. Available at: http://apps.who.int (Дата обращения: 22.05.2018).
  2. Müller T.D, Nogueiras R, Andermann M.L, Andrews Z.B, Anker S.D, Argente J, Batterham R.L, Benoit S.C, Bowers C.Y, Broglio F, Casanueva F.F, D'Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole P.A, Cowley M, Cummings D.E, Dagher A, Diano S, Dickson S.L, Diéguez C, Granata R, Grill H.J, Grove K, Habegger K.M, Heppner K, Heiman M.L, Holsen L, Holst B, Inui A, Jansson J.O, Kirchner H, Korbonits M, Laferrère B, Le Roux C.W, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger P.T, Schwartz T.W, Seeley R.J, Sleeman M, Sun Y, Sussel L, Tong J, Thorner M.O, van der Lely A.J, van der Ploeg L.H, Zigman J.M, Kojima M, Kangawa K, Smith R.G, Horvath T, Tschöp M.H. Ghrelin. Mol Metab. 2015;4(6):437-60. doi: 10.1016/j.molmet.2015.03.005.
  3. Shukla A.P, Mauer E, Igel L.I, Truong W, Casper A, Kumar R.B, Saunders K.H, Aronne L.J. Effect of Food Order on Ghrelin Suppression. Diabetes Care. 2018;41(5):e76-e77. doi: 10.2337/dc17-2244
  4. Poher A.L, Tschöp M.H, Müller T.D. Ghrelin regulation of glucose metabolism. Peptides. 2018;100:236-42. doi: 10.1016/j.peptides.2017.12.015
  5. Cummings D.E, Clement K, Purnell J.Q, Vaisse C, Foster K.E, Frayo R.S, Schwartz M.W, Basdevant A, Weigle D.S. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8(7):643-4. doi: 10.1038/nm0702-643
  6. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal M.S, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87(1):240-4. doi: 10.1210/jcem.87.1.8129
  7. Cigdem Arica P, Kocael A, Tabak O, Taskin M, Zengin K, Uzun H. Plasma ghrelin, leptin, and orexin-A levels and insulin resistance after laparoscopic gastric band applications in morbidly obese patients. Minerva Med. 2013;104(3):309-16.
  8. Al Qarni A.A, Joatar F.E, Das N, Awad M, Eltayeb M, Al-Zubair A.G, Ali M.E, Al Masaud A, Shire A.M, Gumaa K, Giha H.A. Association of Plasma Ghrelin Levels with Insulin Resistance in Type 2 Diabetes Mellitus among Saudi Subjects. Endocrinol Metab (Seoul). 2017;32(2):230-40. doi: 10.3803/EnM.2017.32.2.230
  9. Hill N.R, Nick S.O, Choudhary P, Levy J.C, Hindmarsh P, Matthews D.R. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 2011;13(9):921-8. doi: 10.1089/dia.2010.0247
  10. Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества контроля гликемии и риска осложнений. Сахарный диабет. 2014;17(2):76-82. doi: 10.14341/DM2014276-82
  11. Suh S, Kim J.H. Glycemic variability: How do we measure it and why is it important? Diabetes Metab J 2015;39:273-82. doi: 10.4093/dmj.2015.39.4.273
  12. Ali T.M, Mehanna O.M, El Askary A. The association between ghrelin levels and markers of arterial stiffness and inflammatory markers in Saudi subjects with metabolic syndrome. Diabetes Metab Syndr. 2017;11(Suppl 2):S721-S725. doi: 10.1016/j.dsx.2017.05.005
  13. Zhang S, Zhang Q, Zhang L, Li C, Jiang H. Expression of ghrelin and leptin during the development of type 2 diabetes mellitus in a rat model. Mol Med Rep. 2013;7(1):223-8. doi: 10.3892/mmr.2012.1154
  14. Belinova L, Kahleova H, Malinska H, Topolcan O, Windrichova J, Oliyarnyk O, Kazdova L, Hill M, Pelikanova T. The effect of meal frequency in a reduced - energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study. PLoS One. 2017;12(4):e0174820. doi: 10.1371/journal.pone.0174820
  15. Santiago-Fernández C, García-Serrano S, Tome M, Valdes S, Ocaña-Wilhelmi L, Rodríguez-Cañete A, Tinahones FJ, García-Fuentes E, Garrido-Sánchez L. Ghrelin levels could be involved in the improvement of insulin resistance after bariatric surgery. Endocrinol Diabetes Nutr. 2017;64(7):355-62. doi: 10.1016/j.endinu.2017.05.002
  16. Amato M.C, Guarnotta V, Giordano C. Body composition assessment for the definition of cardiometabolic risk. J Endocrinol Invest. 2013;36(7):537-43. doi: 10.3275/8943
  17. Jonas M.I, Kurylowicz A, Bartoszewicz Z, Lisik W, Jonas M, Domienik-Karlowicz J, Puzianowska-Kuznicka M. Adiponectin/resistin interplay in serum and in adipose tissue of obese and normal - weight individuals. Diabetol Metab Syndr. 2017;9:95. doi: 10.1186/s13098-017-0293-2
  18. Terra X, Auguet T, Quesada I, Aguilar C, Luna A.M, Hernández M, Sabench F, Porras J.A, Martínez S, Lucas A, Pellitero S, Llutart J, del Castillo D, Richart C. Increased levels and adipose tissue expression of visfatin in morbidly obese women: the relationship with pro - inflammatory cytokines. Clin Endocrinol (Oxford). 2012;77(5):691-8. doi: 10.1111/j.1365-2265.2011.04327.x
  19. Chang Y.H, Chang D.M, Lin K.C, Shin S.J, Lee Y.J. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta - analysis and systemic review. Diabetes Metab Res Rev. 2011;27(6):515-7. doi: 10.1002/dmrr.1201
  20. Huang X, Yang Z. Resistin's, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest. 2016;39(6):607-15. doi: 10.1007/s40618-015-0408-2
  21. Klimontov V.V, Myakina N.E. Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. Diabetes Metab Syndr. 2017;11(2):119-24. doi: 10.1016/j.dsx.2016.08.023
  22. Birketvedt G.S, Geliebter A, Kristiansen I, Firgenschau Y, Goll R, Florholmen J.R. Diurnal secretion of ghrelin, growth hormone, insulin binding proteins, and prolactin in normal weight and overweight subjects with and without the night eating syndrome. Appetite. 2012;59(3):688-92. doi: 10.1016/j.appet.2012.07.015
  23. Tong J, Davis H.W, Gastaldelli A, D'Alessio D. Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1. J Clin Endocrinol Metab. 2016;101(6):2405-14. doi: 10.1210/jc.2015-4154
  24. Rizzo M, Rizvi A.A, Sudar E, Soskic S, Obradovic M, Montalto G, Boutjdir M, Mikhailidis D.P, Isenovic E.R. A review of the cardiovascular and anti - atherogenic effects of ghrelin. Curr Pharm Des. 2013;19(27):4953-63. doi: 10.2174/1381612811319270018
  25. Neale J.P.H, Pearson J.T, Katare R, Schwenke D.O. Ghrelin, MicroRNAs, and Critical Limb Ischemia: Hungering for a Novel Treatment Option. Front Endocrinol (Lausanne). 2017;8:350. doi: 10.3389/fendo.2017.00350
  26. Laurila M, Santaniemi M, Kesäniemi Y.A, Ukkola O. High plasma ghrelin protects from coronary heart disease and Leu72Leu polymorphism of ghrelin gene from cancer in healthy adults during the 19 years follow-up study. Peptides. 2014;61:122-9. doi: 10.1016/j.peptides.2014.09.012
  27. Барбараш О.Л., Груздева О.Л., Акбашева О.Е., Белик Е.В., Учасова Е.Г., Каретникова В.Н., Федорова Т.С. Биохимические показатели, ассоциированные с развитием сахарного диабета через год после перенесенного инфаркта миокарда. Клиническая медицина 2014;92(11):52-9. doi: 10.15829/1560-4071-2014-3-87-94

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies